NCT00068289已完成2 期
A Phase II Trial of PS-341 (NSC-681239) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 91
研究概览
简要总结
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have recurrent or refractory extensive-stage small cell lung cancer that was previously treated with platinum-based chemotherapy (such as cisplatin, carboplatin, or oxaliplatin).
详细描述
OBJECTIVES:
- Determine the efficacy of bortezomib, in terms of response rate (confirmed and unconfirmed, complete and partial), in patients with recurrent or refractory extensive stage small cell lung cancer previously treated with platinum-based therapy.
- Determine the qualitative and quantitative toxic effects of this drug in these patients.
- Determine the overall survival of patients treated with this drug.
- Correlate selected molecular markers with outcomes in patients treated with this drug.
OUTLINE: Patients are stratified according to platinum-sensitivity status (platinum sensitive [temporarily closed to accrual as of 8/1/04] vs platinum refractory [temporarily closed to accrual as of 6/1/04]).
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months for 2 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed extensive stage small cell lung cancer
- •Diagnosis by sputum cytology allowed provided it is confirmed by an independent pathologic review
- •Clinical evidence of recurrent or refractory disease does not require a confirmatory biopsy
- •Measurable disease by plain radiographs, CT scan, or MRI
- •Prior radiotherapy to measurable disease allowed provided there is evidence of disease progression by CT scan OR there is measurable disease outside of the radiotherapy field
- •Must have received a prior platinum-based chemotherapy regimen and meet criteria for 1 of the following:
- •Platinum-sensitive disease, defined as an initial response with subsequent progression more than 90 days after last platinum treatment (temporarily closed to accrual as of 8/1/04)
- •Platinum-refractory disease, defined as no response to or progression during platinum treatment or subsequent progression no more than 90 days after last platinum treatment (temporarily closed to accrual as of 6/1/04)
- •Brain and/or leptomeningeal metastases are allowed provided all of the following are true:
- •Asymptomatic on neurological exam
- •No concurrent corticosteroids for symptom control
- •No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin or phenobarbital)
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Zubrod 0-1
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Not specified
- •Creatinine no greater than upper limit of normal OR
- •Creatinine clearance at least 60 mL/min
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •No symptomatic sensory neuropathy greater than grade 1
- •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other adequately treated stage I or II cancer currently in complete remission
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •Not specified
- •Chemotherapy
- •See Disease Characteristics
- •At least 3 weeks since prior chemotherapy
- •Endocrine therapy
- •See Disease Characteristics
- •Radiotherapy
- •See Disease Characteristics
- •At least 3 weeks since prior radiotherapy
- •No concurrent radiotherapy to measurable lesions
- •At least 14 days since prior thoracic or other major surgery and recovered
- •Must have disease outside of the prior surgical resection area OR new lesion must be present
排除标准
- 未提供
研究者
研究点 (91)
Loading locations...
相似试验
已完成
2 期
Bortezomib in Treating Patients With Mantle Cell LymphomaLymphomaNCT00030875NCIC Clinical Trials Group30
已完成
2 期
Bortezomib in Treating Patients With Waldenstrom's MacroglobulinemiaLymphomaNCT00045695NCIC Clinical Trials Group27
已完成
2 期
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaRecurrent Bladder CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerStage IV Urethral CancerTransitional Cell Carcinoma of the BladderUreter CancerNCT00072150National Cancer Institute (NCI)40
已完成
2 期
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterTransitional Cell Cancer of the Renal Pelvis and UreterBladder CancerNCT00066352University Health Network, Toronto
已完成
2 期
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal JunctionEsophageal CancerNCT00107341Alliance for Clinical Trials in Oncology37